Prostate Cancer, Prostate Neoplasms
Conditions
Keywords
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Abiraterone Acetate, Docetaxel, Prednisone, Dexamethasone
Brief summary
The purpose of this study is to evaluate the maximum safe dose of abiraterone acetate administered in combination with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Detailed description
This is an open-label (patients and their doctors will know the identity of study drug administered), uncontrolled (patients are not assigned to treatment by chance), multicenter safety study of escalating dose levels of abiraterone acetate administered in combination with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). This study is conducted in 2 parts. Part I consists of Screening, Treatment, assessment of dose-limiting toxicity (DLT), and determination of the maximum tolerated dose (MTD). Participants are enrolled in sequential 6-subject cohorts (groups) and administered combination therapy (abiraterone acetate and docetaxel plus prednisone) according to a dose-escalation schedule. The abiraterone acetate dose in this study will escalate from 500 mg to 1000 mg daily until the MTD is determined. The MTD is the highest combination dose among the dose combinations investigated in this study at which no more than 2 (33%) of the patients in a cohort experience a DLT. A DLT is defined by an adverse event occurring from Day 1 Week 2 (first dose of abiraterone acetate) to the day before the Day 1 Week 7 docetaxel infusion (3 weeks after the second docetaxel infusion); non-hematological toxicity \>=Grade 3; Grade 4 neutropenia lasting more than 5 days, neutropenia complicated by fever, or systemic infection; thrombocytopenia \<25,000/mcL, or any thrombocytopenia requiring platelet transfusion; and, any subjectively intolerable toxicity. Part II of the study consists of Continuing Treatment, when patients remain at the allocated dose level, escalate to the combination MTD, or discontinuation of docetaxel (if toxicity or intolerability develops) and continue abiraterone acetate (up to 1000 mg/day) plus prednisone, until disease progression; End of Treatment, when posttreatment efficacy and safety will be documented; and Follow-Up, when survival status and new antitumor therapy are monitored. Blood samples for pharmacokinetic and efficacy measurements will be collected at selected times during the study. Safety will be monitored. The total duration of study participation may be up to 36 months. Oral abiraterone acetate will be administered as a single daily dose (500, 750, or 1000 mg). Docetaxel will be administered once every 3 weeks as an intravenous (IV) infusion (60 or 75 mg/m2) over 1 hour. Study participants will premedicate with oral dexamethasone 8 mg 1, 3, and 12 hours before the start of each docetaxel IV infusion. Oral prednisone 5 mg will be administered twice daily.
Interventions
DRUGCohort 4
Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
DRUGCohort 3
Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
DRUGCohort 2
Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
DRUGCohort 1
Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
Sponsors
Cougar Biotechnology, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adenocarcinoma of the prostate * Metastatic disease documented by bone, computed tomography (CT), or magnetic resonance image (MRI) scan * Surgical or medical castration with testosterone less than 50 ng/dL * Prostate cancer progression documented by 1 of the following: PSA progression according to Prostate Cancer Working Group 2 (PCWG2) criteria, radiographic progression by modified Response Evaluation Criteria in Solid Tumors (RECIST) or bone scan * Absolute neutrophil count \>1,500 cells/mm3 * Platelets \>100,000/µl * Hemoglobin \>=10.0 g/dL * Eastern Cooperative Group (ECOG) status score of \<=2.
Exclusion criteria
* Elevated liver function tests (LFTs): Serum bilirubin \>upper limit of normal (ULN), alanine (ALT) or aspartate (AST) aminotransferase \> 1.5 ULN concomitant with alkaline phosphatase \> 2.5 ULN * Small cell carcinoma of the prostate * Pulmonary or brain metastasis, liver metastasis is allowed if LFTs are not elevated * Pre-existing neuropathy or severe fluid retention * Prior cytotoxic chemotherapy for metastatic prostate cancer * Prior therapy with other CYP17 inhibitor(s) or investigational agent(s) targeting the androgen receptor for metastatic prostate cancer * Treatment of primary tumor within 4 weeks of Day 1 Week 1 with surgery, radiation, chemotherapy or immunotherapy * Use of investigational drug within 4 weeks of Day 1 Week 1 or current enrollment in an investigational drug or device study * Prior ketoconazole for prostate cancer * Recent history of ischemic heart disease, electrocardiogram (ECG) abnormalities, or atrial fibrillation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with a dose-limiting toxicity | Up through Week 6 |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with prostate-specific antigen (PSA) response | Up to Month 36 |
| Time to PSA progression | Up to Month 36 |
| Objective response rate | Up to Month 36 |
| Radiographic progression-free survival | Up to Month 36 |
| Survival | Up to Month 36 |
Countries
United States
Outcome results
None listed